These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21455242)

  • 1. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.
    Meyer CH; Holz FG
    Eye (Lond); 2011 Jun; 25(6):661-72. PubMed ID: 21455242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
    Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
    Wylegała E; Teper SJ
    Klin Oczna; 2007; 109(1-3):97-100. PubMed ID: 17687925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on 'Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab'.
    Vallance JH
    Eye (Lond); 2012 Jan; 26(1):167; author reply 167-8; discussion 168. PubMed ID: 22056862
    [No Abstract]   [Full Text] [Related]  

  • 8. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
    Ziemssen F; Grisanti S; Bartz-Schmidt KU; Spitzer MS
    Drugs Aging; 2009; 26(4):295-320. PubMed ID: 19476398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
    Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
    Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
    Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
    Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
    Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
    Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M; Nagpal K; Nagpal PN
    Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
    Meyer CH; Helb HM; Eter N
    Ophthalmologe; 2008 Feb; 105(2):125-38, 140-2. PubMed ID: 18256841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [VEGF inhibitors in ophthalmology].
    Thys J; Dupont G; Rakic JM
    Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.